← Back to Search


ADX-2191 (intravitreal methotrexate 0.8%) for Proliferative Vitreoretinopathy

Phase 3
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up efficacy assessment period (week 1 to week 24)
Awards & highlights


This trial is testing a new drug to see if it can help prevent a serious eye condition.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~efficacy assessment period (week 1 to week 24)
This trial's timeline: 3 weeks for screening, Varies for treatment, and efficacy assessment period (week 1 to week 24) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrent retinal detachment
Secondary outcome measures
Best-corrected visual acuity (BCVA) change from baseline

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ADX-2191 (intravitreal methotrexate 0.8%)Experimental Treatment1 Intervention
ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
Group II: Standard surgical care procedureActive Control1 Intervention
Standard procedure performed.
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-2191 (intravitreal methotrexate 0.8%)
Completed Phase 3

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
31 Previous Clinical Trials
4,454 Total Patients Enrolled
~19 spots leftby Jul 2025